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There are some arguments between the use of hydroxyapatite and porous coating. Some studies have shown that
there is no difference between these two coatings in total hip arthroplasty (THA), while several other studies
have shown that hydroxyapatite has advantages over the porous one. We have collected the studies in
Pubmed, MEDLINE, EMBASE, and the Cochrane library from the earliest possible years to present, with the
search strategy of “(HA OR hydroxyapatite) AND ((total hip arthroplasty) OR (total hip replacement)) AND
(RCT* OR randomiz* OR control* OR compar* OR trial*)”. The randomized controlled trials and comparative
observation trials that evaluated the clinical and radiographic effects between hydroxyapatite coating and
porous coating were included. Our main outcome measurements were Harris hip score (HHS) and survival,
while the secondary outcome measurements were osteolysis, radiolucent lines, and polyethylene wear. Twelve
RCTs and 9 comparative observation trials were included. Hydroxyapatite coating could improve the HHS (p < 0.01),
reduce the incidence of thigh pain (p = 0.01), and reduce the incidence of femoral osteolysis (p = 0.01), but
hydroxyapatite coating had no advantages on survival (p = 0.32), polyethylene wear (p = 0.08), and radiolucent
lines (p = 0.78). Hydroxyapatite coating has shown to have an advantage over porous coating. The HHS and
survival was duration-dependent—if given the sufficient duration of follow-up, hydroxyapatite coating would
be better than porous coating for the survival. The properties of hydroxyapatite and the implant design had
influence on thigh pain incidence, femoral osteolysis, and polyethylene wear. Thickness of 50 to 80 μm and
purity larger than 90% increased the thigh pain incidence. Anatomic design had less polyethylene wear.
Keywords: Hydroxyapatite, Porous, Harris hip score, Survival, Total hip arthroplastyIntroduction
Total hip arthroplasty (THA) is one of the most wide
operations in orthopedic practice [1]. Cement was widely
used, but high rates of failure of cemented femoral com-
ponents in active patients have been reported. Cemented
primary THAs showed excellent results in the short-
term but deteriorated with time, while uncemented pri-
mary THAs were not only satisfactory in the short-term
but also tended to improve with time. Moreover, some
studies showed that uncemented and cemented THAs
had the comparable clinical results during the follow-up
of 6 years, which stimulated the development of implant* Correspondence: charleschen1991@gmail.com
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unless otherwise stated.with uncemented fixation. The uncemented THAs with
porous coating allowed bone ingrowth to achieve a rigid
fixation. But the problem of osteolysis and stress shield-
ing meant that the long-term stability of uncemented
THA was still in question [2,3]. Meanwhile, uncemented
stem fixation had the shortcoming of thigh pain. To
address such problem, bioactive coating has been added
to uncemented component to enhance the fixation by
osseointegration of implant, of which hydroxyapatite (HA)
was the most popular one.
HA coating accelerates bone healing and enhances the
biologic fixation of implant due to its biocompatibility
and osteoconductive potential. Several studies have shown
that it could reduce the migration of HA-coated prosthetic
components and have better results and higher survival
rate than identical press-fit components [4]. However,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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from the stem surface may induce osteolysis either by
stimulating bone loss or by migration to the joint space
producing third-body wear [5]. Concerns have been raised
regarding the technique and parameters that were used in
applying the coating to the stem as well [6]. Most reviews
of clinical results, X-ray findings, and revision rates were
unable to find the significant difference between hydroxy-
apatite and non-hydroxyapatite-coated stems [7-12]. Some
studies showed that hydroxyapatite-coated components
could ensure earlier return to activity, reduction in thigh
pain, and fewer radiolucent lines [13-16].
A previous meta-analysis by Gandhi et al. [17] based
on nine studies including 1,764 samples showed that
survival from aseptic loosening had no difference be-
tween the two groups at a mean follow-up of 6.5 years,
and the mean Harris hip score (HHS) between these
groups demonstrated the same. Another meta-analysis by
Goosen et al. [18] with eight RCTs including 857 samples
reported the clinical and radiographic results, and there
was no difference in HHS, endosteal bone ingrowth, and
radioactive lines in the surface area of the prosthesis.
The former analysis only included four RCTs of nine
studies, and one of which did not show clear HHS data,
and the HA stem was grit-blasted, while porous stem
was not. The latter analysis did not target new studies
published in the later years. It is essential to update the
previous results based on the following reasons. (1) The
up-to-date 12 RCTs and comparative studies enlarged the
sample size to 9,860 and expanded the population distribu-
tion. (2) Compared to the average follow-up of 5.4 years in
the previous analysis, the longer 7.5 years of the new ana-
lysis may lighten on the long-term efficacy of HA coating
for HHS, survival, or radiolucent lines. (3) Insufficient data
in the previous meta-analysis led to the incomprehensive
evaluation of the potential influential factors on HA coat-
ing effects, including the thickness and purity of HA coat-
ing, the implant design, and the duration of follow-up. The
present analysis updated the meta-analysis on the effects of
HA-coated stems on clinical and radiographic results, such
as HHS, survival, and thigh pain incidence.
Methods
Electronic databases were searched with the limited lan-
guage of English. The result was last updated on Dec. 17,
2012. The search used the following term and Boolean op-
erators: “(HA OR hydroxyapatite) AND ((total hip arthro-
plasty) OR (total hip replacement)) AND (RCT* OR
randomiz* OR control* OR compar* OR trial*)”. The ref-
erence lists of all the selected articles were hand-searched
for any additional trials. If necessary, we contacted authors
to collect additional information.
The trials was included if (1) the patients had trauma,
arthritis, or other diseases requiring total hip arthroplastywith age not less than 18, (2) the inclusion of the compari-
son between a proximally HA/porous coated femoral and
a proximal porous coated stem who underwent primary
uncemented total hip arthroplasty, (3) the measurement
of outcome was at least by one of the following clinical
and radiographic results, including Harris hip score, sur-
vival, thing pain incidence, radiolucent lines, femoral oste-
olysis, and polyethylene wear, and (4) they were published
randomized controlled trials or comparison observational
studies. Trials were excluded if (1) the patients underwent
cemented THAs or revision uncemented THAs, (2) the
trials were phase I or case report or review or animal
models, or only the abstract was available, (3) the coating
was only on the cup not the stem, (4) the follow-up was
less than 1 year, and (5) they were sub-analysis of previ-
ously published meta-analyses.
Two of us (CYL and SMM) independently assessed each
trial with a 12-item scale [19], assessing factors such
as randomization, allocation concealment, and blindness.
We resolved disagreements through discussion.
For each eligible trial, we extracted relevant data and
checked the accuracy. In instances of unreported stand-
ard error for a mean difference in HHS, we calculated
the standard error by converting the p value to a z-score
and solving for the standard error with the formula: z =
mean difference/standard error [20]. If the article did
not have a certain p value and only a range, we just ex-
cluded the data [13,21,22]. For the trials [13], which had
more than one intervention group with different ranges
of HA coating, we combined group B and group C into
one intervention group. For the trials [23,24], in which
some identical patients were included but with different
durations of follow-up, we included both of them to
evaluate HHS.
Our main outcome measurements were mean postop-
erative HHS and the survival of prosthesis from aseptic
loosening. We also assessed the incidence of thigh pain
and radiographic results. To improve the clinical relevance,
we used the weighed mean difference (WMD) and then es-
timated the relative difference in the change from baseline
as the absolute benefit divided by the mean of all the base-
line means of the control groups. With the fixed effect
model, WMD and 95% confidence intervals (95% CI) were
calculated and the data pooling was done using Review
Manager 5.1.7.
We calculated the statistical heterogeneity using a χ2
test on N − 1 degrees of freedom (N = sample size), with
significance at 0.05. We also assessed the inconsistency
I2 using the formula [(Q − df)/Q] × 100% (Q = the χ2 stat-
istic, df = degree of freedom) to describe the percentage
of the variability in effect estimates due to the heterogen-
eity [19]. We considered I2 value of 25%, 50%, and 75%
as low, medium, and high heterogeneity, respectively.
A fixed effects model was used if there was no statistical
Figure 1 A flowchart illustrated the selection process of eligible trials in our meta-analysis.
Figure 2 Funnel plot for HHS shows no publication bias.
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random effects model.
We developed several subgroup analyses not only to
explain the heterogeneity but also to identify the factors









Camazzola et al. [28] RCT 61 (34/27) 48.2 ± 9.0/
50.4 ± 8.7
22/3
Dorr et al. [16] Retrospective,
matched pair
30 (15/15) 55 (38–71) 10/5
Hamadouche et al.
[34]
RCT 45 (22/23) 65/64 41/3
Incavo et al. [32] RCT 50 (24/26) 55 NR
Kim et al. [23] RCT 100 (50/50) 45.3 (27–61) 14/3
Kim et al. [24] RCT 110 (55/55) 46.3 (27–63) 39/1
Lee and Lee 2007
[33]
RCT 40 (20/20) 44 (25–72) 2/18





131 (46/85) 52 (29–72)/
51 (22–78)
67/9
Mcpherson et al. [36] Retrospective,
matched pair
84 (42/42) 55 ± 11.4/
56.5 ± 11.7
36/4
Parvizi et al. [9] Prospective,
matched-pair
86 (43/43) 66.8 ± 6.2/
65.7 ± 5.9
NR
Paulsen et al. [38] Retrospective
comparison
3,158/4,749 NR 3,83
Ranawat et al. [35] RCT 174 (92/82) 54.9 (29.4–67.5)/
55.5 (28.6–71.8)
38/1
Rothman et al. [10] Retrospective,
matched pair





136 (68/68) 54 (23–66)/
56 (22–67)
56/8
Sano et al. [39] Retrospective,
observational
study
55 (24/31) 64.0 (51–83)/
62.7 (41–80)
49/3
Santori et al. [14] Retrospective,
observational
study
227 (158/69) NR NR
Søballe et al. [4] RCT 26 (14/12) 56.8 (48–63)/
58.6 (50–68)
NR
Tanzer et al. [22] RCT 39 (17/22) 66 (54–80)/
64 (43–78)
13/2





Yee et al. [30] RCT 62 (35/27) 48.2 ± 9.0/
50.4 ± 8.7
11/2
Yoon et al. [29] RCT 75 (37/38) 45.3 (20–69)/
46.0 (23–71)
14/4
RCT randomized controlled trials, HA hydroxyapatite, NR not reported, THA total hipresults, such as the design of study, thickness, and purity
of hydroxyapatite, follow-up duration, and implant type.
Because there was revalent data showing that 50 to 80 μm
was the acceptable standard [25,26], 50 to 80 μm was
chosen to be the interval of HA thickness. Six-yeardistribution
ale/male)
Inclusion criteria
9 Men younger than 60 years and women younger than
65 years having elective primary THA
Patients who underwent bilateral primary THA
9 Patients with osteoarthritis of the hip requiring THA
Patients who underwent THA
6 Patients who underwent sequential bilateral primary THA
6 Patients who underwent bilateral primary THA
Patients who had late-stage bilateral osteonecrosis were
randomly treated with bilateral THA
7 Patients who underwent THA using a MHP
8 Patients of the same gender, bone type, activity level,
and diagnosis, ages within 5 years, weight within
25 pounds, Charnley activity class
The patients matched for age, sex, weight, diagnosis,
Charnley class, operative approach, bone quality,
femoral head size, type of acetabular component,
and duration of follow-up
4/4,073 Patients underwent primary uncemented THA, who
were younger than 70 years of age at surgery
14 Patients received cementless THA with the Ranawat-Burstein
metaphyseal-diaphyseal fit hip system
9 Consecutive THA with use of Taperloc stem, matched
for age, sex, weight, diagnosis, Charnley class, operative
approach, and duration of follow-up
0 Patients who had a primary hip replacement with
insertion of either a porous-coated or HA-coated
Omniflex femoral componene
Patients in whom surgery was performed at least
2 years before the present study
Patients underwent THA with the anatomic prosthesis
Patients who underwent THR to receive prosthetic
with either Ti-alloy coating or HA coating
6 Patients undergoing a cementless THA
165 All patients who underwent cementless THA
2 Men younger than 60 years of age and women younger
than 65 years of age undergoing primary THA
9 Patients who underwent THA use a multilock femoral
stem with or without HA/TCP coating
arthroplasty, TCP tricalcium phosphate.
Table 2 Details of co-factors and measurement of studies
Study Purity and
thickness of HA
Surgery approach Co-factors Follow-up
(years)
Missing information Hip implant Outcome measurement
Camazzola
et al. [28]
NR Hardinge approach Routine antibiotic prophylaxis;
anticoagulation with dicumarin
was used preoperatively and for
a total of 3 months postoperatively,





4 patients were lost to follow-up, 8
died. 1 refuced to participate in the






Dorr et al. [16] 94% purity,
50–60 μm












administration of systemic antibiotics
for 48 h, preventative anticoagulation
therapy until full weight-bearing, and
NSAID for 5 days to prevent heterotopic
ossification, partial weight-bearing was
allowed for 6 weeks followed by full
weight-bearing
9.18 (3.93–10.28) One patient from each group died
from an unrelated cause at three
months and at 27 months after
surgery, three patients were lost to
follow-up at a mean of three years,
of these, one belonged to the HA
and two to the GB group
Profile (DePuy) HHS, radiographic outcome
Incavo et al.
[32]
NR NR NR 4 no ProWle (DePuy) HHS, radiographic outcome
Kim et al. [23] 30 μm Posterolateral
approach
Stand on the second postoperative day.
Partial weight-bearing with crutches as
tolerated, full weight-bearing was allowed
at 6 weeks after surgery








Kim et al. [24] 30 μm Posterolateral
approach
NR 15.6 (15–16) 3 were lost to follow-up, 2 died IPS femoral stem
(DePuy)
HHS, WOMAC, thigh pain,










Hip joint motion and ambulation using
a wheelchair were allowed from the first
postoperative week, crutch walking with
partial weight-bearing began 3 to 4 weeks
after the second operation. In addition, the
patients used a cane for additional 2 to
4 months until they could walk well
without any support
143 (123–168) 4 patients died, 5 patients were
lost






NR Routine clinical evaluation was
performed under the supervision
of the operative surgeons
14.5 (10.2–16.6)/
16.9 (11.4–18.5)
27 patients in the MHP group and 5
patients in the MHP HA group were
decreased from causes unrelated to
the index surgery. In addition, 14
patients (14 hips, 10.8%) in the MHP
group and nine patients (10 hips,
16.4%) in the MHP HA group had not
returned for minimum 10-year follow-






























Table 2 Details of co-factors and measurement of studies (Continued)
Parvizi et al. [9] NR NR NR 9.2 ± 4.8/10.1 ± 4.6 Each one of the members of nine

















5 (3–8) for thigh
pain, 17.7 + −0.8
(16.3–20)
53 patients were deceased, 28
















NR Prophylactic antibiotics were given
intravenously at the time of the
operation and were continued for
48 h. Ten milligrams of low-dose
warfarin was given on the night
of the operation, instructed to bear
only 10% of the body weight on
the affected limb for 6 weeks, at
which time, they progressed to use
of a cane












Sano et al. [39] NR Posterior approach Partial weight-bearing was allowed
1 week after the operation, with
full weight-bearing after 3 weeks








NR Partial weight bearing with two
canes was allowed on the fifth
postoperative day and progressed
to one cane on day 30
70 m (60–84) No Anatomic prosthesis
(Zimmer)






Prophylactic antibiotics and anti-
thromboembolic drugs, mobilized
on the third postoperative day and
instructed to walk with protected
weight-bearing for the first six
postoperative weeks
1 11 patients were excluded from
RSA because of technical errors,
1 patient with bilateral THR died
from unrelated disease
Biometric (Biomet) HHS, the visual analog scale







All patients remained non-weight-



















All patients were non-weight-bearing
for 6 weeks postoperatively, followed
by progressive weight-bearing as
tolerated
37 m (2–5 years) 16 patients in the group with
uncoated and 11 patients in the
group with coated components
withdraw or were lost to follow-up;




















Table 2 Details of co-factors and measurement of studies (Continued)





sodium) was administered before surgery
and 48 h after surgery; anticoagulation with
dicumarin was given: 5 mg orally the night
before surgery and daily for a duration of
3 months after surgery. Physical therapy was
commenced on the first or second day after
surgery. Tough weight-bearing with crutches
for 6 weeks was allowed for uncomplicated
cases. Progression to full weight-bearing as
tolerated was allowed after 6 weeks
4.6 (3–7) 6 patients were lost to follow-up, 1
died of cardiac causes.1 patient
declined additional participation in
the study after surgery, 1 with
bilateral THA was involved in a motor
vehicle accident that resulted in a










Instruted to walk with partial
weight-bearing with the aid of 2
crutches for 4 weeks after surgery
127.4 m (96–144)/
127 (108–144)
2 patients in the coated group
died of myocardial infarction and
cerebral infarction, 2 patients in






HA hydroxyapatite, TCP tricalcium phosphate, NR not reported, HHS Harris hip score, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index scores, RSA Roentgen stereophotogrammetric analysis, HSS













































Hamadouche et al. [34] Yes Unclear Yes Unclear Unclear Yes Yes Yes Yes Yes Yes No High
Incavo et al. [32] Yes Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No High
Kim et al. [23] Yes Yes Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No High
Kim et al. [24] Yes Unclear Yes Yes Unclear Yes Yes Yes Yes Yes Yes No High
Lee and Lee [33] Yes Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No High
Søballe et al. [4] Yes Yes Yes Unclear Unclear Yes Yes Yes Yes Yes Yes No High
Tanzer et al. [22] Yes Yes Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No High
Tanzer et al. [31] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No High
Yee et al. [30] Yes Unclear Yes Unclear Unclear Yes Yes Yes Yes Yes Yes No High
Yoon et al. [29] Yes Yes Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No High
Camazzola et al. [28] Yes Unclear Yes Unclear Unclear Yes Yes Yes Yes No Yes No Moderate
Dorr et al. [16] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear Moderate
Lombardi, Jr. et al. [12] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes No Yes No Moderate
Mcpherson et al. [36] Unclear Unclear Yes Yes Unclear Unclear Yes Yes Yes Yes Yes No Moderate
Parvizi et al. [9] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No Moderate
Paulsen et al. [38] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No Moderate
Ranawat et al. [35] Yes Unclear Yes Unclear Unclear Unclear Yes Yes Yes No Yes No Moderate
Rothman et al. [10] No Unclear Yes No No Yes Yes Yes Yes Yes Yes No Moderate
Sanchez-Sotelo et al. [37] Unclear Unclear Yes Unclear Unclear Unclear Yes Yesc Yes Yes Yes No Moderate
Sano et al. [39] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No Moderate
Santori et al. [14] Unclear Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes No Moderate
aOnly if the method of sequence generated was explicitly described could get a “Yes”; sequence generated by “Dates of Admission” or “Patients Number” received a “No”.
bIntermittent treatment or therapy duration less than 6 months means “Yes”, otherwise “No”.
cDrop-out rate ≥ 20% means “No”, otherwise “Yes”.
dITT intention-to-treat, only if all randomized patients are analyzed in the group they were allocated to could receive a “Yes”.















Figure 3 The forest plot for Harris hip score shows HA coating can improve the post-operative HHS compared with porous coating.
IV inverse variance, HA hydroxyapatite.
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as there was sufficient data available allowing for the sub-
group analysis. Sensitivity analysis was performed through
omitting trials to assess the changes in overall effect. Fun-
nel plots were used to assess publication bias among the
included trials graphically. Bias can be seen if the plots
were widely skewed versus a plot resembling an inverted
triangle which represents no bias [27].
Results
The literature search initially yielded 878 relevant trials.
Two of us (CYL and SMM) reviewed the titles and ab-
stracts of all reviews including two of hand-searched.
Twelve RCTs [4,22-24,28-35] and nine comparative ob-
servation trials [9,10,12,14,16,36-39] were included after
applying our eligibility criteria (Figure 1). Funnel plots in-
dicated no publication bias (Figure 2). We recorded the
characteristics of 21 trials that were included (Table 1)
and details of co-factors and measurement (Table 2). All
studies reported a minimum 1 year (median 7.5 years,Figure 4 The forest plot for thigh pain incidence shows that HA coatingrange 1 to 17.7). We assessed the quality of included trials
with the 12-item scale (Table 3). However the intention-
to-treat analysis was rarely reported, and no outcome was
selectively reported in all studies.
The results showed that the HA presented higher
HHS than the porous group (15 trials, N = 1,353, WMD=
1.66, 95% CI 0.71 to 2.60, p = 0.0006) (Figure 3), could
decrease the thigh pain incidence (6 trials, N = 724, OR =
0.53, 95% CI 0.32 to 0.87, p = 0.01) (Figure 4), and had less
femoral osteolysis (5 trials, N = 386, OR = 0.52, 95% CI
0.31 to 0.86, p = 0.01) (Figure 5), while there was no differ-
ence in the survivorship from aseptic loosening (16 trials, N=
9,472, RR= 1.00, 95% CI 1.00 to 1.00, p=0.32) (Figure 6),
polyethylene wear (4 trials, N = 347, WMD= −0.02, 95%
CI −0.04 to 0.00, p = 0.08) (Figure 7) and radiolucent lines
(6 trials, N = 566, OR = 0.95, 95% CI 0.67 to 1.35, p = 0.78)
( Figure 8) between the two groups.
There were no heterogeneities for HHS (I2 = 0%), sur-
vivorship from the aseptic loosening (I2 = 0%), radiolucent
lines (I2 = 0%), or femoral osteolysis (I2 = 46%). The resultscan reduce it compared with porous coating. HA hydroxyapatite.
Figure 5 The forest plot for femoral osteolysis shows that HA coating has less osteolysis compared with porous coating. HA hydroxyapatite.
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geneous in some degree (I2 = 56%; I2 = 96%). The hetero-
geneity of thigh pain incidence can not be explained by the
study design, quality of study, thickness of HA, implant de-
sign or follow-up duration maybe because of the potential
co-factors, such as weight-bearing after the operation. As
to the limitation of this analysis, we could not set this sub-
group analysis. The polyethylene wear can not be explained
by purity of HA and duration of follow-up. But when we
classified the polyethylene wear into subgroups by the
thickness of HA (50–80 μm and >80 μm or < 50 μm) and
implant design (anatomic and non-anatomic), the hetero-
geneity could no longer be observed (I2 = 0%).
Subgroup analysis for HHS, survival of implant from
aseptic loosening, and radiolucent lines indicated that
the included non-RCTs did not affect the RCTs (p =
0.42; p = 0.27; p = 0.98; p = 0.52), while as to incidence of
thigh pain and femoral osteolysis, there was a slight dif-
ference (p = 0.02; p = 0.05). Our results showed that theFigure 6 The forest plot for survival from aseptic loosening shows no dilonger duration of follow-up tends to have higher HHS
(p = 0.11) than the shorter one (WMD= 2.21, 95% CI
1.05 to 3.37 for duration of follow-up > 6 years; WMD =
0.58, 95% CI −1.04 to 2.20 for duration < 6 years) and
likewise for the survival (p = 0.11, RR = 1.01 95% CI 0.99
to 1.03 for duration of follow-up > 6 years, RR = 1.00,
95% CI 0.99 to 1.00 for duration of follow-up < 6 years).
The thickness of HA was larger than 80 μm or less than
50 μm, the purity less than 90%, and the anatomic implant
reduced incidence of thigh pain and the duration of
follow-up did not affect it. It is doubtful that the RCTs
and high-quality study had the high incidence of thigh
pain and femoral osteolysis (Table 4). The overall result
was not significantly altered by omitting trials with a sam-
ple sizes less than 70 or those with imputed data.
Discussion
The primary finding is that HA coating could improve
the postoperative HHS, reduce the incidence of thigh pain,fference between HA coating and porous coating. HA hydroxyapatite.
Figure 7 The forest plot for polyethylene wear shows HA coating has less wear compared with porous coating. IV inverse variance,
HA hydroxyapatite.
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was no statistical difference of femoral stem survivorship
from aseptic loosening, polyethylene wear, and radiolucent
lines between the two groups. In addition, the subgroup
analyses found that HHS tends to improve in the longer
duration of follow-up and so was the prosthetic survival.
The longer duration of follow-up, the better advantage of
HA coating over porous coating for the HHS and sur-
vivorship from aseptic loosening.
In this meta-analysis, we asked: (1) which coating is
better with regard to the clinical and radiologic mea-
surements and (2) which modifying factors affect the
comparative effect between both coatings.
To the best of our knowledge, the present meta-analysis
is the first to comprise all the available comparative obser-
vational evidence and to comprehensively investigate the
difference in HHS and survivorship and radiographic out-
comes between HA and porous coating for THA. As the
previous systematic review only included four RCTs of
nine studies, one of the included studies did not show
clear HHS data and the HA stem was grit-blasted, while
porous stem was not. Another previous systematic review
did not include new studies published in the later years.
We included 12 RCTs and 9 comparison observation
studies and developed explicit inclusion and exclusion cri-
teria. Our analysis quintupled the sample size compared
with previous meta-analysis (9,860 versus 1,764) and hadFigure 8 The forest plot for radiolucent lines shows no difference betlonger duration of follow-up (7.5 years versus 6.5 years).
We performed a comprehensive set of subgroup analyses
and a sensitivity analysis not only to explain the hetero-
geneity but also to provide additional insights into the po-
tential influential factors of HHS, survival, thigh pain, and
other radiographic outcome.
Our meta-analysis has some limitations. (1) There was
variability in the selection criteria of individual trials, in-
cluding the primary disease, gender, ages of patients, and
the type of prosthesis. (2) due to the limited number of
included trials, we could not analyze the influence of
other clinically relevant factors, such as complications
of THA, BMD, and WOMAC osteoarthritis index. (3)
Missing information such as declining participation and
crossover led to incomplete data and potentially bias.
(4) The small sample size in the subgroup analysis re-
duced the precision of the pooled estimates and the
ability to detect the statistical significance of some vari-
ables, that is, polyethylene wear. More RCTs would be
warranted to clarify them. (5) With the limitation of in-
cluded studies, we can not analyze the effect of implant
design, which needs more study to assess.
One of the most significant results of our analysis is
that HA coating had higher HHS and less incidence of
thigh pain. The advantage of an HA coating includes su-
perior proximal femoral osteointegration and better pres-
ervation of periprosthetic bone quality. The patients withween HA coating and porous coating. HA hydroxyapatite.
Table 4 Subgroup analysis of the included studies by different influential factors







RR (95% CI) Subgroups
(numbers)
OR (95% CI) Subgroups
(numbers)
OR (95% CI) Subgroups
(numbers)










RCT (4) 0.73 (0.42,
1.28)





Non-RCT (5) 2.29 (0.50,
4.07)
Non-RCT (6) 1.00 (0.99,
1.00)
Non-RCT (2) 0.14 (0.04,
0.49)
Non-RCT (2) 0.96 (0.41,
2.24)
Non-RCT (3) 0.39 (0.22,
0.70)
Non-RCT (0)
p = 0.42 p = 0.27 p = 0.02 p = 0.98 p = 0.05
Study
quality
High (9) 1.41 (0.30,
2.52)
High (8) 1.01 (0.99,
1.02)
High (3) 1.29 (0.57,
2.88)
High (4) 0.95 (0.65,
1.39)
High (2) 1.24 (0.38,
4.13)
High (4) N.A.
Moderate (6) 2.28 (0.50,
4.07)
Moderate (8) 1.00 (0.99,
1.00)
Moderate (3) 0.30 (0.15,
0.57)
Moderate (2) 0.96 (0.41,
2.24)
Moderate (2) 0.42 (0.24,
0.74)
Moderate (0)
p = 0.42 p = 0.27 p = 0.006 p = 0.98 p = 0.11
Thickness
of HA
50–80 μm (8) 0.76 (−0.63,
2.15)
50–80 μm (10) 1.00 (0.99,
1.00)
50–80 μm (3) 0.71 (0.40,
1.27)






















p = 0.24 p = 0.23 p = 0.04 p < 0.00001
Purity of
HA
>90% (4) −0.09 (−3.04,
2.86)
>90% (7) 1.00 (0.99,
1.00)
>90% (2) 0.68 (0.36,
1.26)
>90% (3) 0.73 (0.31,
1.71)




<90% (3) 0.82 (−0.77,
2.42)
<90% (3) 1.00 (0.98,
1.02)
<90% (3) 0.23 (0.08,
0.65)
<90% (2) 0.93 (0.61,
1.40)




p = 0.59 p = 0.72 p = 0.08 p = 0.63 p = 0.4 p = 0.79
Implant
design
Anatomic (5) 1.65 (0.15,
3.16)
Anatomic (4) 1.02 (0.99,
1.05)
Anatomic (2) 0.19 (0.06,
0.58)
Anatomic (1) 0.32 (0.07,
1.47


























p = 1.00 p = 0.24 p = 0.04 p = 0.15 p = 0.52 p < 0.00001
Follow-up
duration
>6 years (9) 2.21 (1.05,
3.37)
>6 years (10) 1.01 (0.99,
1.03)
>6 years (4) 0.56 (0.29,
1.08)
>6 years (2) 0.58 (0.24,
1.43)
>6 years (4) 0.44 (0.24,
0.77)
>6 years (3) −0.02
(−0.02, −0.01)
<6 years (6) 0.58 (−1.04,
2.20)
<6 years (6) 1.00 (0.99,
1.00)
<6 years (2) 0.50 (0.24,
1.05)
<6 years (4) 1.04 (0.71,
1.52)
<6 years (1) 1.00 (0.32,
3.15)
<6 years (1) 0.01
(−0.06, 0.08)
p = 0.11 p = 0.11 p = 0.82 p = 0.25 p = 0.2 p = 0.46
Study design and study quality would affect the incidence of thigh pain and study design has influence on femoral osteolysis. When the thickness of HA is <50 or >80 μm, it has less thigh pain incidence and
polyethylene wear. The anatomic implant has less incidence of thigh pain and polyethylene wear.
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dence of activity-related trochanteric and thigh pain [35].
The thickness and purity of HA and implant design could
affect the incidence of thigh pain. The incidence decreased
abruptly after the first postoperative year [40]. Thigh pain
following uncemented hip arthroplasty was generally tran-
sient and would disappear over time.
Femoral osteolysis and polyethylene wear could result
to gradual subsidence or loosening of implant. Some
studies showed that HA coating had less osteolysis and
polyethylene wear [37,16], but in Almeida’s study, with
the use of HA coated stem, they still found 38% of oste-
olysis and 41% of polyethylene wear in the hips. Their
stems were mostly used in young patients, who had
greater activity compared to the older patients which
might have been the affecting factor. From the retrieved
specimen, some studies found that HA coating could in-
crease the amount of ingrowth and attachment of bone
leading to the enhanced biological fixation [41]. More-
over, HA-coated Ti implants can achieve a much higher
degree of bone apposition and mechanical stability com-
pared to the implants without such a coating [26]. The
heterogeneity of polyethylene wear can not be explained
by purity of HA and duration of follow-up. But when we
classified the polyethylene wear into subgroups by the
thickness of HA (50–80 μm and >80 μm or < 50 μm)
and implant design (anatomic and non-anatomic), the
heterogeneity could no longer be observed.
The geometry design of the implant has a large impact
on the clinical outcome. Joshi’s study explored the hy-
pothesis that through redesign, a total hip prosthesis
could be developed to substantially reduce stress shielding,
then reduce the loosening of the prosthesis [42]. Dopico-
González assessed effects of implant design geometry by
probabilistic finite element tool, she thought the geometry
of the implant design clearly affected the sensitivities of
maximum nodal micromotion [43]. As the limitation of
included studies, we just divided the implant into ana-
tomic and non-anatomic. It needs more studies to assess
the effect of implant design. Our study showed that
anatomic implant had less incidence of thigh pain and
reduced polyethylene wear. Ando et al. found that FMS-
anatomic stem reduced the proximal stem-bone relative
motion and transferred more load to the proximal femur
compared to conventional symmetric stems and the FMS,
which resulted in better biomechanical stability at least in
the early postoperative period [44]. Another study showed
an excellent clinical outcome and 98.3% survival of ABG
II implant with HA coating [45]. In Cao’s study, they also
thought that an anatomically designed prosthesis can pro-
vide good clinical results, with low incidence of thigh pain
and loosening of the component [46].
HA is biocompatible and osteoconductive and in con-
tact with bone often develops a mechanically tight bond.Human retrieval studies have shown that HA-coated
stem observed significantly more ingrowth and attachment
of the bone [47].
Conclusion
In conclusion, HA is better than porous coating. HA
coating could improve the postoperative HHS, reduce
the incidence of thigh pain, and reduce the incidence of
femoral osteolysis, while there was no statistical difference
of femoral stem survivorship from aseptic loosening, poly-
ethylene wear, and radiolucent lines between the two
groups.
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